[{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Zinc","moa":"||B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selenious Acid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"CHRISTUS Health","sponsor":"Pharco Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selenious Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CHRISTUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CHRISTUS Health \/ Pharco Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"CHRISTUS Health \/ Pharco Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Selenous Acid

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Selenious Acid Injection is a trace element indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 31, 2022

                          Lead Product(s) : Selenious Acid

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CHRISTUS Health

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          CHRISTUS Health

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 03, 2021

                          Lead Product(s) : Selenious Acid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Pharco Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Multrys™ is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

                          Product Name : Multrys

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          February 09, 2021

                          Lead Product(s) : Zinc,Copper,Selenious Acid

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank